The Sanford Lorraine Cross Award for medical innovation: Advancing a rigorous and repeatable method for recognizing translational research leaders who today are bringing emerging transformative innovations to patients
Medical innovation awards stand out as an important means to focus public attention on what matters in medical advancement. Traditional awards typically focus on celebrating medical innovators with either a track record of proven successes in new treatments or promising basic science breakthroughs still years away from reaching patients. Perhaps one of the greatest challenges for medical innovation that is not sufficiently addressed by these traditional awards is celebrating translational research efforts on the cusp of major advancements where medical innovators are demonstrating success in bringing emerging transformative medical innovations to patients. As a part of its award process, the Sanford Lorraine Cross Award has developed a unique method to fill this gap in the landscape of medical innovation awards for ongoing translational research efforts by identifying promising medical innovations within a narrow spectrum of the research pipeline on the verge of having transformative impact for patients in the near term. The Sanford Lorraine Cross Award addresses the challenges of identifying emerging transformative medical innovations making their way through development by deploying a rigorous, analytically-based “early signals analysis” to identify emerging transformative medical innovations in its selection process independent of the medical innovators who are succeeding in bringing them forward. It also stands apart from traditional medical innovation awards in focusing on identifying award candidates that have significant roles in bringing the emerging transformative medical innovation across the finish line to patients, and their efforts in overcoming challenges, forging collaborations and ensuring a successful outcome. The data-driven award selection process used for the Lorraine Cross award ultimately inverts the standard medical award selection paradigm – truly innovative areas of discovery and breakthrough science are identified independently of candidates and used to then focus candidate selection on the areas with the most promising transformative potential for patients. This article sets out the details of how the Sanford Award makes use of leading tools and methods in identifying transformative innovations currently in translational research to provide another important focus of what matters in medical innovation.
Relevance for patients: The Sanford Lorraine Cross Award identifies the most successful application of translational research that ultimately expedited development of a treatment or cure of a disease.
[1] National Institutes of Health. Lasker Awards, 2017. Bethesda, Maryland: National Institutes of Health; 2019.
[2] Berkley S. The Power of Vaccines and how Gavie has Helped make the World Healthier. JAMA 2019;322:1251-2.
[3] Nobel Media AB. Nomination and Selection of Medicine Laureates. Nobel Media AB; 2020.
[4] Albert L, Mary WL. The Lasker Awards, 2019.New York: Lasker Foundation; 2019.
[5] Breakthrough Prize. Life Sciences, 2019. New York: Breakthrough Prize; 2019.
[6] Administration USDoHaHSFaD. Innovation of Stagnation: Challenges and Opportunity on the Critical Path to New Meidcal Technologies; 2004. p. 3.
[7] Huang YC, Tat M, Kristina L. Identifying Transformative Scientific Research. IEEE 13th International Conference on Data Mining. Dallas, Texas: IEEE; 2013.
[8] Staudt J, Yu H, Light RP, Marschke G, Börner K, Weinberg BA. High-impact and Transformative Science (HITS) Metrics: Definition, Exemplification, and Comparison. PLoS One 2018;13:e0200597.
[9] MazloumianA, EomYH, Helbing D, LozanoS, Fortunato S. How Citation Boosts Promote Scientific Paradigm Shifts and Nobel Prizes. PLoS One 2011;6:e18975.
[10] Huang YH, Tat M, Nan HC. Identifying Transformative Research in Biomedical Sciences: International Conference on Technologies and Applications of Artificial Intelligence. Taipei, Taiwain: Technologies and Applications of Artificial Intelligence; 2014.
[11] (NIH) NIoH. Request for Applications for Regional Translational Research Center Planning Grants. Services DoHaH; 2004. p. 4.
[12] CharavarthyR, Kristina C, Joseph D, Christopher-Paul M, Nis W. Public and Private Sector Contributions to the Research and Development of the Most Transformational Drugs of the Last 25 Years. Ther Innov Regul Sci 2016;50:759-68.
[13] Cozzens SG, Kang J, Kim KS, Lee HJ, Ordóñez G, Porter A. Emerging Technologies: Quantitative Identification and Measurement. TechnolAnal Strage Manage 2010;22:361-76.
[14] Kesselheim AS, Avorn J. The Most Transformative Drugs of the Past 25 Years: A Survey of Physicians. Nat Rev Drug Discov 2013;12:425-31.
[15] Fuchs VR, Sox HC Jr. Physicians’ Views of the Relative Importance of Thirty Medical Innovations. Health Aff (Millwood) 2001;20:30-42.